Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT
- Conditions
- Interventions
- First Posted Date
- 2017-11-14
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
- Target Recruit Count
- 256
- Registration Number
- NCT03340896
- Locations
- 🇫🇷
Centre Jean Bernard, Le Mans, France
Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)
- Conditions
- Interventions
- First Posted Date
- 2017-11-14
- Last Posted Date
- 2019-12-20
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT03342352
A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer
- First Posted Date
- 2017-11-08
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 205
- Registration Number
- NCT03336216
- Locations
- 🇺🇸
Local Institution - 0006, Philadelphia, Pennsylvania, United States
🇺🇸Local Institution - 0007, Los Angeles, California, United States
🇺🇸Dana Farber Cancer Institute., Boston, Massachusetts, United States
Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer
- Conditions
- Metastatic Biliary Tract CarcinomaMetastatic Pancreatic AdenocarcinomaStage IV Pancreatic Cancer AJCC v6 and v7Stage IVB Colorectal Cancer AJCC v7Metastatic Gastroesophageal Junction AdenocarcinomaStage IV Colorectal Cancer AJCC v7Stage IVA Colorectal Cancer AJCC v7Metastatic Colorectal CarcinomaMetastatic Malignant Digestive System Neoplasm
- Interventions
- First Posted Date
- 2017-11-08
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Academic and Community Cancer Research United
- Target Recruit Count
- 18
- Registration Number
- NCT03337087
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
- Conditions
- Interventions
- First Posted Date
- 2017-11-01
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT03329248
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
- First Posted Date
- 2017-10-19
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 149
- Registration Number
- NCT03314935
- Locations
- 🇺🇸
Northwest Georgia Oncology Centers, Marietta, Georgia, United States
🇺🇸USA Mitchell Cancer Center, Mobile, Alabama, United States
🇺🇸University of Alabama, Birmingham, Alabama, United States
Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA
- First Posted Date
- 2017-10-12
- Last Posted Date
- 2017-12-19
- Lead Sponsor
- Jules Bordet Institute
- Registration Number
- NCT03307941
- Locations
- 🇧🇪
Institut Jules Bordet, Brussels, Belgium
Chemoradiotherapy Versus Esophagectomy After Endoscopic Resection for Superficial Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2017-10-11
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 240
- Registration Number
- NCT03306901
- Locations
- 🇰🇷
National Cancer Center, Goyang-si, Korea, Republic of
🇰🇷Pusan National University Hospital, Pusan, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab
- Conditions
- Interventions
- First Posted Date
- 2017-10-03
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 4
- Registration Number
- NCT03300609
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer
- Conditions
- Locally Advanced Rectal AdenocarcinomaStage IVA Rectal Cancer AJCC v7Stage IIIA Rectal Cancer AJCC v7Stage IIIB Rectal Cancer AJCC v7Stage IV Rectal Cancer AJCC v7Stage IVB Rectal Cancer AJCC v7Metastatic Rectal AdenocarcinomaRectal AdenocarcinomaStage III Rectal Cancer AJCC v7Stage IIIC Rectal Cancer AJCC v7
- Interventions
- First Posted Date
- 2017-10-03
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3
- Registration Number
- NCT03300544
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.